These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9005412)

  • 1. [Volume reduction of the thyroid after radioiodine therapy in patients with autonomous goiter and Basedow's goiter].
    Dederichs B; Otte R; Klink JE; Schicha H
    Nuklearmedizin; 1996 Oct; 35(5):164-9. PubMed ID: 9005412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of radioiodine therapy of manifest hyperthyroidism and autonomous struma with euthyroidism].
    Berding G; Schicha H
    Nuklearmedizin; 1990 Aug; 29(4):158-65. PubMed ID: 2216811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine therapy for thyroid volume reduction of large goitres.
    Bachmann J; Kobe C; Bor S; Rahlff I; Dietlein M; Schicha H; Schmidt M
    Nucl Med Commun; 2009 Jun; 30(6):466-71. PubMed ID: 19381116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Deterioration of endocrine ophthalmology after radioiodine therapy in Graves' disease?].
    Weigand A; Hinzpeter B; Schicha H
    Nuklearmedizin; 1998; 37(7):234-8. PubMed ID: 9830613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of large multinodular goitre using repeated doses of radioiodine.
    Baczyk M; Pisarek M; Czepczyński R; Ziemnicka K; Gryczyńska M; Pietz L; Sowiński J
    Nucl Med Commun; 2009 Mar; 30(3):226-31. PubMed ID: 19262285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in thyroid volume after radioactive iodine therapy in patients with single toxic thyroid nodule].
    Gołkowski F; Jabrocka-Hybel A; Huszno B
    Przegl Lek; 2005; 62(5):284-6. PubMed ID: 16334533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
    Guhlmann CA; Rendl J; Börner W
    Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
    Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
    Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
    Meller J; Siefker U; Hamann A; Hüfner M
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):235-9. PubMed ID: 16804797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of radioiodine therapy on urinary iodine excretion.
    Meller B; Lauer I; Bähre M; Richter E
    Nuklearmedizin; 1998 May; 37(3):107-12. PubMed ID: 9604231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.